Six years since the FDA blessed Sanofi and Regeneron’s Dupixent as the first biologic to treat chronic rhinosinusitis with ...

The FDA on Friday approved a new biologic as add-on maintenance treatment for inadequately controlled chronic rhinosinusitis ...

Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing ...

Dianthus Therapeutics (NASDAQ:DNTH) announced a licensing deal worth up to $1B with Nanjing Leads Biolabs on Thursday to ...

Plaque psoriasis is characterized by the formation of distinct erythematous scaly patches with clear boundaries. 1 The disease results from dysregulation of the innate and adaptive immune systems and ...

In psoriasis, like cancers, disease control that includes the well-being of a patient is an additional useful measure of ...

Excellergy is developing medicines that combat allergic responses in three different ways, a multipronged effect the company ...

Overall, the median duration of b/tsDMARD use was 4.3 years, longer in RA (6.3 years) than axSpA (3 years). TNF inhibitors were the most commonly used treatment (80.7%), with axSpA patients more often ...

APG808 resulted in a rapid and durable decrease from baseline in FeNO and pSTAT6 measurements throughout the 12 weeks.

An experimental Dice Therapeutics drug in development for treating psoriasis now has its first human data showing it reduces the signs and symptoms of the inflammatory skin disorder. The preliminary ...

DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while ...